市场调查报告书
商品编码
1219863
全球肺气肿治疗市场规模、份额和行业趋势分析报告:按药物类型、分销渠道(药店和零售药房、医院药房、在线供应商)、区域展望和预测2022-2028Global Emphysema Treatment Market Size, Share & Industry Trends Analysis Report By Medication Type, By Distribution Channel (Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Providers), By Regional Outlook and Forecast, 2022 - 2028 |
在预测期内,全球肺气肿治疗市场规模预计将以 6.1% 的复合年增长率增长,到 2028 年将达到 60.5 亿美元。
肺气肿的症状包括但不限于焦虑、悲伤、疲劳、睡眠困难和体重减轻。 肺气肿的症状经常被误诊,因为它们与许多其他肺部疾病和其他健康问题有关。 肺气肿引起的呼吸困难会随着时间的推移而恶化,并导致称为慢性阻塞性肺病 (COPD) 的疾病。
COVID-19 影响分析
全球医疗保健行业的流程因 COVID-19 大流行而中断。 该疾病已导致多个不同部门暂时关闭,包括医疗保健行业的许多不同子领域。 另一方面,COVID-19 大流行对市场发展产生了有利影响。 感染冠状病毒会引起类似于慢性阻塞性肺病 (COPD) 的症状。 症状包括呼吸困难以及肺部和其他部位的富氧血液供应不足。 因此,在大流行期间,对用于治疗慢性阻塞性肺病的药物的需求加速了。
市场增长因素
捲烟消费者数量增加
烟草消费是有史以来最大的公共卫生挑战之一,夺走了许多人的生命。 世界卫生组织 (WHO) 估计,烟草使用每年导致超过 800 万人死亡。 其中超过 700 万直接归因于使用烟草产品,约 120 万归因于接触非吸烟者的二手烟。 吸烟习惯最常引起肺气肿。 也有人指出,长期接触其他肺部刺激物如被动吸烟也可能导致 COPD 的发作。 随着世界各地越来越多的人吸烟,预计未来对肺气肿治疗的需求会增加。
空气污染加剧
空气污染的主要来源是家庭、汽车、工业区和森林火灾等燃烧装置。 此外,颗粒物、一氧化碳、二氧化氮、臭氧和二氧化硫等都是关係人体健康的重要污染物。 无论是室内还是室外,空气污染都是导致多种疾病的主要原因,也是全球死亡和残疾的主要原因之一。 此外,世界卫生组织 (WHO) 指出,大约有 24 亿人使用受污染的明火和以煤油、生物质(木材、动物粪便、农作物废料)和煤炭为燃料的简单炉灶。因此,我们估计我们暴露在达到我们家中有害的空气污染水平。 这种烹饪方法会造成危险程度的空气污染。
市场製约因素
影像诊断设备成本
可以通过胸部 X 光诊断肺气肿,并排除其他可能导致呼吸急促的原因。 但是,由于价格非常高,财力有限,许多欠发达国家的医院无法投资诊断影像设备。 此外,对诊断的需求如此之高,尤其是在低收入国家,以至于无力购买最先进成像设备的医院转而转而重建成像设备。 因此,有望成为扩大传染性呼吸道疾病诊断试剂市场的主要障碍。
药物类型展望
按药物类型划分,肺气肿药物市场分为支气管扩张剂、类固醇等。 支气管扩张剂部分将在 2021 年占肺气肿治疗市场的最大收入份额。 支气管扩张剂是一种药物,可以放鬆肺部肌肉,使呼吸更顺畅,同时还能扩张气道(支气管),使呼吸更顺畅。 这一细分市场的扩大可归因于对用于治疗肺气肿的支气管扩张剂的需求增加以及对肺气肿的认识不断增加。
分销渠道前景
肺气肿治疗市场根据分销渠道细分为在线供应商、药店和零售药店以及医院药店。 2021 年,在线提供商部分在肺气肿治疗市场中占据了相当大的收入份额。 这可能与对治疗肺气肿的在线药物供应商的需求不断增加有关。 这消除了患者去医院治疗的需要,有助于扩大市场。 越来越多的在线药品平台也推动了市场的发展。 这是推动行业发展的因素之一。
区域展望
按地区划分,肺气肿治疗市场分为北美、欧洲、亚太地区和 LAMEA。 到 2021 年,亚太地区将占肺气肿治疗市场的主要收入份额。 这是由于几个变量造成的,包括用于生产高质量肺气肿药物的支出增加。 越来越多地使用不同的三联製剂治疗肺气肿也推动了市场的发展。 由于吸烟者人数不断增加,印度的慢性阻塞性肺病 (COPD) 发病率也是最高的。 这些因素结合在一起,使亚太地区成为肺气肿治疗的诱人需求。
The Global Emphysema Treatment Market size is expected to reach $6.05 billion by 2028, rising at a market growth of 6.1% CAGR during the forecast period.
Due to the excessive inflammation of the alveoli, emphysema is also known as chronic obstructive disease. This is because the condition causes both breathing and exhalation to slow down. Damage caused by emphysema to the air sacs may result in a change in the form of the air sacs or, more often, their destruction. This leads to a reduction in the amount of gas that is exchanged in the lungs, which in turn causes trouble breathing. This occurs because the damage to the alveoli results in inadequate room for air to enter the sacs, which causes air to get trapped within the alveoli.
By treating the patient with bronchodilators and steroids, it is possible to alleviate the patient's shortness of breath and cut down on the required hospitalizations. Chronic obstructive pulmonary disease (also known as COPD) is the third most significant cause of mortality globally, accounting for 3.23 million deaths in 2019. This information comes from the World Health Organization. Countries with low and intermediate incomes are responsible for about 90 percent of all COPD-related fatalities in people under the age of 70. (LMIC). COPD is caused by long-term exposure to toxic gases and particles with individual variables such as events that impact the formation of the lungs in infancy and heredity. Chronic obstructive pulmonary disease (COPD) results in ongoing and progressively worsening respiratory symptoms, such as difficulty breathing, coughing, and producing phlegm.
Other symptoms may include but are not limited to anxiety, sadness, weariness, difficulty sleeping, and weight loss. Emphysema is often misdiagnosed since the symptoms it displays are also associated with a variety of other lung illnesses and other health issues. The difficulty breathing brought on by emphysema may worsen over time and lead to a condition known as a chronic obstructive pulmonary disease (COPD).
COVID-19 Impact Analysis
The global healthcare industry has seen a disruption in processes due to the COVID-19 pandemic. The sickness has caused several different sectors, including numerous different sub-domains of the healthcare industry, to close their doors temporarily. On the other hand, the COVID-19 pandemic had a beneficial influence on the development of the market. Patients infected with the coronavirus basically suffer from the same symptoms as those with chronic obstructive pulmonary disease (COPD). These symptoms include difficulty breathing and an inadequate supply of oxygen-rich blood to the lungs and the rest of the body. As a result, the demand for drugs used to cure chronic obstructive pulmonary disease accelerated during the pandemic.
Market Growth Factors
Rising Number Of Tobacco Consumers
Tobacco consumption is one of the most significant challenges to the world's public health that it has ever encountered, and it is responsible for the deaths of many individuals. According to projections made by the World Health Organization, tobacco use results in more than 8 million deaths each year. More than 7 million of these fatalities are directly attributable to the use of tobacco products, while around 1.2 million are attributable to the exposure of non-smokers to second-hand smoke. The habit of smoking cigarettes almost often brings on emphysema. In addition, there is evidence that chronic exposure to other lung irritants, such as passive smoking, may also contribute to the development of COPD. As a result of the growing number of people who smoke tobacco throughout the globe, it is projected that the need for emphysema treatment will also rise in the years to come.
Increasing Levels Of Air Pollution
The most prevalent contributors to air pollution are combustion appliances found in homes, motor vehicles, industrial sites, and forest fires. In addition, particulate matter, carbon monoxide, nitrogen dioxide, ozone, and sulphur dioxide are significant pollutants that concern the public's health. Air pollution, both outside and inside, is a significant contributor to various illnesses and is one of the leading causes of death and disability worldwide. In addition, the World Health Organization (WHO) estimates that approximately 2.4 billion people are subjected to potentially harmful levels of air pollution in their homes as a result of their use of polluting open fires or simple stoves for cooking that are fueled by kerosene, biomass (wood, animal dung, and crop waste), and coal. These types of cooking methods produce dangerous levels of air pollution.
Market Restraining Factors
Expenses Incurred For Imaging Equipment
It is possible to support a diagnosis of advanced emphysema with an X-ray of the chest and rule out other potential reasons for shortness of breath. However, because of the prohibitively high prices and limited financial resources, many hospitals in underdeveloped countries cannot invest in diagnostic imaging equipment. Furthermore, because of the strong demand for diagnostic procedures, particularly in low-income countries, hospitals who do not have the financial resources to purchase brand-new imaging systems that are on the bleeding edge of technology decide instead to employ imaging systems that have been rebuilt. As a result, throughout the time that is anticipated, this aspect will constitute a substantial obstacle to the expansion of the market for infectious respiratory illness diagnostics.
Medication Type Outlook
Based on Medication Type, the Emphysema Treatment Market is segmented into Bronchodilators, steroids, and others. In the emphysema treatment market in 2021, the bronchodilators segment accounted for the largest revenue share. Bronchodilators are a class of drugs that relax the muscles in the lungs, which makes breathing easier, and widens the airways, which also makes breathing easier (bronchi). The expansion of this market segment may be attributed to an increase in the demand for bronchodilators as a therapy for emphysema and increased knowledge about the condition.
Distribution Channel Outlook
Based on the distribution channel, the Emphysema Treatment Market is classified into online providers, drug stores & retail pharmacies, and hospital pharmacies. The online providers segment registered a considerable revenue share in the emphysema treatment market in 2021. This may be linked to the fact that there has been an increase in demand for online providers that provide pharmaceuticals for the treatment of emphysema. This eliminates the need for patients to go to hospitals for treatment, contributing to the market expansion. In addition, a growing number of online platforms for medicine delivery is also driving the market. This is another factor that is driving the industry.
Regional Outlook
Based on region, the Emphysema Treatment Market is segmented into North America, Europe, Asia Pacific, and LAMEA. In 2021, the Asia Pacific region accounted for a significant revenue share in the emphysema treatment market. This is because of several variables, including an increase in spending in producing high-quality medications for emphysema. The increasing use of different triple combination formulations for the treatment of emphysema is also driving the expansion of the market. In addition, due to an increase in the number of people who smoke, India has the highest chronic obstructive pulmonary disease (COPD) rate. These factors combine to make Asia-Pacific an attractive need for emphysema treatment.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Viatris, Inc., Orion Corporation, GlaxoSmithKline PLC, Pfizer, Inc., Hikma Pharmaceuticals PLC, Boehringer Ingelheim International GmbH and Verona Pharma Plc.
Strategies Deployed in Emphysema Treatment Market
Jan-2023: AstraZeneca Plc received the US approval for Airsupra. Airsupra was formerly known as PT027. Airsupra is a pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol and an anti-inflammatory inhaled corticosteroid (ICS) in the US and is being developed by Avillion and AstraZeneca. Furthermore, Airsupra is used for the treatment or prevention of bronchoconstriction.
Nov-2022: AstraZeneca Plc came into partnership with C4X Discovery Holdings, a Drug Discovery company. Under this partnership, AstraZeneca Plc would be able to develop and deal with an oral treatment for the chronic obstructive pulmonary disease (COPD), respiratory illnesses, and inflammatory illnesses as well. Moreover, both partners would be focusing on creating C4XD's NRF2 Activator program with a primary focus on COPD.
Apr-2022: GlaxoSmithKline Plc Pharmaceuticals Limited unveiled the Trelegy Ellipta. Trelegy Ellipta is the first single-inhaler triple therapy (SITT) in India for Chronic Obstructive Pulmonary Disease (COPD) patients. Moreover, healthcare professionals have a new once-daily, single inhaler triple therapy for the excellent treatment of their COPD patients in India.
Mar-2022: Viatris Inc. and Kindeva Drug Delivery L.P. received the U.S. Food and Drug Administration (FDA) approval for Breyna(Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol). Breyna is a drug-device combination product that is meant for certain patients with chronic obstructive pulmonary disease (COPD) or Asthma. This new drug device would be available in 80 mcg/4.5 mcg and 160 mcg/4.5 mcg dosage strengths.
Jul-2021: GlaxoSmithKline plc received the US Food and Drug Administration (FDA) approval for the Nucala (mepolizumab). Nucala (mepolizumab) is a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). This is helpful for adult patients 18 years of age and older with inadequate response to nasal corticosteroids.
Jun-2021: Teva Pharmaceuticals Industries Ltd. unveiled the First Generic Version of PERFOROMIST a formoterol fumarate inhalation solution, 20 mcg/2 ML. The new generic version is used to treat bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis.
Dec-2020: AstraZeneca PLC received the approval from European Union (EU) for Trixeo Aerosphere. Trixeo Aerosphere is used for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Jul-2020: Novartis AG received the European Commission (EC) approval for Enerzair Breezhaler as a maintenance treatment of asthma in adult patients. This approval contains an optional digital companion with a sensor and an app that delivers medication reminders, inhalation confirmation, and access to objective data to help therapeutic conclusions.
Jul-2020: AstraZeneca Plc received approval from the US for the Breztri Aerosphere. Breztri Aerosphere is used for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Additionally, Breztri Aerosphere is a triple-combination therapy.
Jul-2020: Teva Pharmaceutical Industries Ltd. unveiled the ProAir Digihaler(albuterol sulfate 117 mcg) Inhalation Powder. ProAir Digihaler is the first and only digital rescue inhaler demonstrated in patients that are four years or older for the prevention or treatment of bronchospasm. Additionally, the device comes with built-in Bluetooth ® Wireless Technology sensors that connect to the mobile app and deliver inhaler event information.
Feb-2019: Orion Corporation came into partnership with Propeller Health, a leading digital therapeutics company. Under this partnership, Orion Corporation would be able to combine the Easyhaler line of inhalers for COPD and Asthma with Propeller's digital medicine platform. Moreover, through this step, Orion Corporation would be able to provide its patients and their providers with a unique capability to enhance the user experience of Easyhaler products and aid patients in sufficiently adhering to the treatments.
Jul-2018: Orion Corporation partnered with Menarini Group, an Italian pharmaceutical company. Under this partnership, Orion Corporation would be able to commercialize and distribute Orion's Easyhaler products in 10 countries in the Asia-Pacific region. Furthermore, the countries involved are Thailand, Singapore, South Korea, China, The Philippines, Indonesia, Taiwan, Malaysia, Hong Kong, and Vietnam.
Market Segments covered in the Report:
By Medication Type
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures